Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men

Y. Sunila Reddy, S. Karl Gotzkowsky, Joseph J. Eron, Julie Y. Kim, William D. Fiske, Susan A. Fiscus, Leslie Anne Petch Lee, Myron S. Cohen, Angela D.M. Kashuba

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influence sexual transmission of human immunodeficiency virus (HIV) type 1. This study compared the pharmacokinetic, pharmacodynamic, and dose responses of efavirenz (EFV) in SP versus those in blood plasma (BP). A total of 431 BP samples and 157 SP samples were obtained over a period of 40 days, from 9 EFV-naive men (i.e., men about to receive EFV for the first time) and from 12 EFV-experienced men (i.e., men already receiving EFV as part of an antiretroviral regimen). Overall, median EFV exposure in SP was 3.4% (range, 2.0%-5.0%) of that in BP. However, all EFV concentrations in SP were ≤40-fold higher than the wild-type IC90 (IC90WT) for HIV-1. During the dosing interval, no single SP:BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP. By day 40, HIV-1 RNA in SP was undetectable in 8 (89%) of 9 EFV-naive men and remained undetectable in 10 (83%) of 12 EFV-experienced men. In SP, EFV reaches concentrations above the HIV-1 IC90WT throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP.

Original languageEnglish (US)
Pages (from-to)1339-1343
Number of pages5
JournalJournal of Infectious Diseases
Volume186
Issue number9
DOIs
StatePublished - Nov 1 2002

Fingerprint

efavirenz
Semen
HIV-1
Pharmacokinetics
RNA
Anti-Retroviral Agents

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Reddy, Y. S., Gotzkowsky, S. K., Eron, J. J., Kim, J. Y., Fiske, W. D., Fiscus, S. A., ... Kashuba, A. D. M. (2002). Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. Journal of Infectious Diseases, 186(9), 1339-1343. https://doi.org/10.1086/344311

Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. / Reddy, Y. Sunila; Gotzkowsky, S. Karl; Eron, Joseph J.; Kim, Julie Y.; Fiske, William D.; Fiscus, Susan A.; Petch Lee, Leslie Anne; Cohen, Myron S.; Kashuba, Angela D.M.

In: Journal of Infectious Diseases, Vol. 186, No. 9, 01.11.2002, p. 1339-1343.

Research output: Contribution to journalArticle

Reddy, YS, Gotzkowsky, SK, Eron, JJ, Kim, JY, Fiske, WD, Fiscus, SA, Petch Lee, LA, Cohen, MS & Kashuba, ADM 2002, 'Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men', Journal of Infectious Diseases, vol. 186, no. 9, pp. 1339-1343. https://doi.org/10.1086/344311
Reddy, Y. Sunila ; Gotzkowsky, S. Karl ; Eron, Joseph J. ; Kim, Julie Y. ; Fiske, William D. ; Fiscus, Susan A. ; Petch Lee, Leslie Anne ; Cohen, Myron S. ; Kashuba, Angela D.M. / Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. In: Journal of Infectious Diseases. 2002 ; Vol. 186, No. 9. pp. 1339-1343.
@article{606cbaa5edea4ff78ed2514e8a313def,
title = "Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men",
abstract = "Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influence sexual transmission of human immunodeficiency virus (HIV) type 1. This study compared the pharmacokinetic, pharmacodynamic, and dose responses of efavirenz (EFV) in SP versus those in blood plasma (BP). A total of 431 BP samples and 157 SP samples were obtained over a period of 40 days, from 9 EFV-naive men (i.e., men about to receive EFV for the first time) and from 12 EFV-experienced men (i.e., men already receiving EFV as part of an antiretroviral regimen). Overall, median EFV exposure in SP was 3.4{\%} (range, 2.0{\%}-5.0{\%}) of that in BP. However, all EFV concentrations in SP were ≤40-fold higher than the wild-type IC90 (IC90WT) for HIV-1. During the dosing interval, no single SP:BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP. By day 40, HIV-1 RNA in SP was undetectable in 8 (89{\%}) of 9 EFV-naive men and remained undetectable in 10 (83{\%}) of 12 EFV-experienced men. In SP, EFV reaches concentrations above the HIV-1 IC90WT throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP.",
author = "Reddy, {Y. Sunila} and Gotzkowsky, {S. Karl} and Eron, {Joseph J.} and Kim, {Julie Y.} and Fiske, {William D.} and Fiscus, {Susan A.} and {Petch Lee}, {Leslie Anne} and Cohen, {Myron S.} and Kashuba, {Angela D.M.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1086/344311",
language = "English (US)",
volume = "186",
pages = "1339--1343",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men

AU - Reddy, Y. Sunila

AU - Gotzkowsky, S. Karl

AU - Eron, Joseph J.

AU - Kim, Julie Y.

AU - Fiske, William D.

AU - Fiscus, Susan A.

AU - Petch Lee, Leslie Anne

AU - Cohen, Myron S.

AU - Kashuba, Angela D.M.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influence sexual transmission of human immunodeficiency virus (HIV) type 1. This study compared the pharmacokinetic, pharmacodynamic, and dose responses of efavirenz (EFV) in SP versus those in blood plasma (BP). A total of 431 BP samples and 157 SP samples were obtained over a period of 40 days, from 9 EFV-naive men (i.e., men about to receive EFV for the first time) and from 12 EFV-experienced men (i.e., men already receiving EFV as part of an antiretroviral regimen). Overall, median EFV exposure in SP was 3.4% (range, 2.0%-5.0%) of that in BP. However, all EFV concentrations in SP were ≤40-fold higher than the wild-type IC90 (IC90WT) for HIV-1. During the dosing interval, no single SP:BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP. By day 40, HIV-1 RNA in SP was undetectable in 8 (89%) of 9 EFV-naive men and remained undetectable in 10 (83%) of 12 EFV-experienced men. In SP, EFV reaches concentrations above the HIV-1 IC90WT throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP.

AB - Therapeutic concentrations of antiretroviral agents in seminal plasma (SP) may reduce virus burden and influence sexual transmission of human immunodeficiency virus (HIV) type 1. This study compared the pharmacokinetic, pharmacodynamic, and dose responses of efavirenz (EFV) in SP versus those in blood plasma (BP). A total of 431 BP samples and 157 SP samples were obtained over a period of 40 days, from 9 EFV-naive men (i.e., men about to receive EFV for the first time) and from 12 EFV-experienced men (i.e., men already receiving EFV as part of an antiretroviral regimen). Overall, median EFV exposure in SP was 3.4% (range, 2.0%-5.0%) of that in BP. However, all EFV concentrations in SP were ≤40-fold higher than the wild-type IC90 (IC90WT) for HIV-1. During the dosing interval, no single SP:BP EFV-concentration ratio was significantly predictive of the absolute measure of exposure in SP. By day 40, HIV-1 RNA in SP was undetectable in 8 (89%) of 9 EFV-naive men and remained undetectable in 10 (83%) of 12 EFV-experienced men. In SP, EFV reaches concentrations above the HIV-1 IC90WT throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP.

UR - http://www.scopus.com/inward/record.url?scp=0036838801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036838801&partnerID=8YFLogxK

U2 - 10.1086/344311

DO - 10.1086/344311

M3 - Article

VL - 186

SP - 1339

EP - 1343

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 9

ER -